Controlling Drug Release

This expertise stems from our ability to evaluate a compound’s physicochemical properties and its pharmacokinetic and pharmacodynamic characteristics. Using this knowledge, we can proactively engineer novel drug release profiles that can improve a drug's therapeutic performance and further enhance the market potential of our products.

Eurand’s Controlling Drug Release (CDR)Technology Platform

Our CDR technology platform is broad, applicable to a wide range of molecules, and commercially proven. We have four technologies within this platform and can choose the best technology or combination of technologies to achieve the most efficacious plasma concentration profile for a given therapeutic agent. We seek to address the specific needs of a compound such as reduced drug dosage, enhanced therapeutic effect and optimized safety and toxicity profiles. Using our CDR technologies, we have developed many product formulations; including Diffucaps^® Sodium Diclofenac, Diffucaps^® Diltiazem, Diffutab^® Isosorbide-5-Mononitrate and Eurand Minitabs^® Nifedipine, which are currently being sold in many countries by our licensees.

Eurand's CDR Technology Platform Includes:

Diffucaps^®

Diffutab^®

Eurand Minitabs^®

Orbexa^®